Platelet Counts Further Refine Classification of Renal-Cell Carcinoma

French and Italian researchers designed a study to improve treatment options for patients with clear-cell renal-cell carcinoma (ccRCC) at intermediate-risk by better characterizing their classification. RCC Renal Cell Carcinoma Written on Green Key of Metallic Keyboard. Finger pressing key. Listen to an audio version of this article A treatment plan for patients with cancer depends acutely on the current stage and progression rate it is discovered in, as well as the type of cancer it is. The more precisely a patients’ risk can be assessed, the more exact their treatment plan can be. This leads directly to better patient outcomes. One way to gauge a patients’ risk is to use a risk-stratified method. Risk stratification is the systematic classification of patients based on the current status of their health and the number of negative clinical prognostic factors that they present with. From Gustave Roussy, the Gustave Roussy Institute, and the University of Paris-Saclay—each in Villejuif, France—and the University of Modena and Reggio Emilia in Modena, Italy, researchers used a risk-stratified database from the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) to carry out a study designed to better characterize intermediate-risk patients with clear-cell renal-cell carcinoma (ccRCC). The primary goal of the study was to use the information gathered to more precisely tailor treatment for patients with ccRCC in the intermediate-risk classified group. This research paper was chosen as the cover paper of Oncotarget’s Vol 11, Issue #49. IMDC Risk Stratification Model The IMDC model of risk stratification uses six negative clinical prognostic factors, including: performance status, hemoglobin level, time between diagnosis and the start of treatment, corrected serum calcium, neutrophil count, and platelet count. “The International Metastatic renal cell carcinoma Database Consortium (IMDC) score is currently used as a prognostic index to stratify patients with mRCC in three subgroups: good, intermediate and poor-risk groups [1, 2].” Patients that have three or more of the negative clinical prognostic factors above are considered to be in the poor-risk (of death) outcome group, with the average overall survival estimated at a mere eight months. Patients that present with only one or two of these factors are considered to be in the intermediate-risk group, with the average survival predicted to be approximately 23 months. Out of 777 patients identified with metastatic ccRCC and treated with an anti-VEGF pathway inhibitor, 51% were classified in the intermediate-risk group. Despite the classification, each of these patients had a different prognosis and the total overall survival was only 27%. Therefore, the researchers argue that patients categorized in the intermediate-risk group should not be treated with the same therapeutic regimen, and designed a study to further categorize this group. Refining the Intermediate-Risk Classification Researchers in this study used three approaches to further analyze the intermediate-risk group of patients with metastatic ccRCC in the IMDC risk stratification model and then compared them. The first approach analyzed the classification based on the number of risk factors patients presented with. They found that the median overall survival was longer by 15 months for patients who presented with only one prognostic factor, as opposed to two. Approach number two analyzed the classification based on a multivariable Cox regression model with backward selection.

Комментарии

Отправить комментарий

Популярные сообщения из этого блога

Oncotarget: Targeted lymphodepletion with a CD45-directed antibody radioconjugate

  Oncotarget   recently published " Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy " which reported that Chimeric antigen receptor T cell therapies, and adoptive cell therapy in general, represent one of the most promising anti-cancer strategies. In contrast to relatively non-specific chemotherapy-derived lymphodepletion, targeted lymphodepletion with radioimmunotherapy directed to CD45 may be a safer and more effective alternative to target and deplete immune cells. Here the authors describe the results of preclinical studies with an anti-mouse CD45 antibody 30F11, labeled with two different beta-emitters 131Iodine and 177Lutetium, to investigate the effect of anti-CD45 RIT lymphodepletion on immune cell types and on tumor control in a model of adoptive cell therapy. Treatment of mice with 3.7 MBq 131I-30F11 or 1.48 MBq 177Lu-30F11 safely depleted immune cells such as spleen CD4 and CD8 T C
Далее...

Oncotarget: Survival after resection of brain metastases: A matched cohort analysis

 The cover for issue 32 of Oncotarget features Figure 2, "This figure depicts overall survival and local in-brain recurrence-free survival in the study's subgroups," by Hussein, et al. which reported that the aim of the present study is to assess whether the use of 5-ALA has an impact on local recurrence or survival compared to conventional white light microscopic tumor resection. Two groups were compared:      In the “white light” group, resection was performed with conventional microscopy.      In the 5-ALA group, fluorescence guided peritumoral resection was additionally performed after standard microscopic resection. Local in-brain recurrence occurred in 21/175 patients with a rate of 15/119 in the white light and 6/56 in the 5-ALA group. The use of 5-ALA did not result in lower in-brain recurrence or mortality compared to the use of white light microscopy. Dr. Bawarjan Schatlo from the Department of Neurosurgery at The University of Medicine Goettingen said, "
Далее...

Trending with Impact: MSRE-PCR Detects Hypermethylated DNA in Tumors

Researchers identify genomic regions in DNA with hypermethylation, abundant MSRE sites, and low methylation levels that can be amplified and detected using MSRE-PCR analysis in diverse types of tumor DNA and normal tissue. Oncotarget oncotarget journal impact factor A pair of U.S. researchers from Johns Hopkins University in Baltimore, Maryland, and from Genmab—an international biotech company in Princeton, New Jersey—collaborated in a study to demonstrate: “Selective amplification of hypermethylated DNA from diverse tumor types via MSRE-PCR.” This study was published as the cover paper of journal Volume 11, Issue #47 in Oncotarget. Methylation Errors “Oncotarget” Methylation is an important process in multiple functions in human DNA, including gene regulation and silencing through the recruitment of proteins. After every cellular DNA replication cycle, DNA methyltransferase (DNMT) enzymes aid in performing on-the-spot DNA methylation to lock genes in the “off” position. DNMT enzy
Далее...